OFEV Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving OFEV Growth

1. Blockbuster status with sustained multi-billion revenue base

• OFEV generated ~$3.8 billion in global sales in 2023, with ~12.8% YoY growth
• Sales further increased to ~€3.8 billion (~$4.1B) in 2024 (+~9%)
• Ranked among top global drugs with ~$4.07B sales in 2024
• A strong and expanding revenue base ensures durable growth and continued investment, making OFEV a core product for Boehringer Ingelheim.

2. Broad and expanding label across fibrosing lung diseases

• Initially approved for idiopathic pulmonary fibrosis (IPF), later expanded to:
• Systemic sclerosis-associated ILD (SSc-ILD)
• Chronic fibrosing ILDs with progressive phenotype (approved 2020)
• Recent expansion includes pediatric patients (EU approval in 2025)
• Label expansion significantly increases the addressable patient population, driving volume growth across pulmonology.

3. Strong clinical efficacy in slowing disease progression

• OFEV is a tyrosine kinase inhibitor targeting VEGF, FGF, and PDGF pathways involved in fibrosis
• Clinical trials show significant reduction in decline of forced vital capacity (FVC) in IPF and other ILDs (widely published in peer-reviewed literature).
• Demonstrated ability to slow disease progression (not just symptoms) supports:
• Physician preference
• Long-term chronic use
• Reimbursement acceptance

4. High unmet need and growing ILD prevalence

• IPF and progressive ILDs are chronic, fatal diseases with limited treatment options
• Increasing diagnosis rates and aging population are expanding the treatable pool globally
• Persistent unmet need ensures steady demand growth, especially as awareness and diagnosis improve.

5. Limited generic competition (current exclusivity advantage)

• As of 2023-2024, no widespread generic competition has impacted OFEV sales significantly
• Competitor drug (pirfenidone) has already faced generic erosion, benefiting OFEV uptake

6. Strong contribution to company growth and global expansion

• OFEV is consistently cited as a key growth driver alongside Jardiance in Boehringer's portfolio
• Growth driven across US, Europe, and Japan, with strong uptake in respiratory medicine.
• Global penetration and increasing physician familiarity drive steady volume expansion.

OFEV Recent Developments

In March 2025, Boehringer Ingelheim announced today that The European Commission (EC) approved OFEV (Nintedanib) in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs), and in adolescents and children aged 6 years and older for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). The decision follows a recommendation for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) last December.

"OFEV Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of OFEV for approved indication like Idiopathic pulmonary fibrosis, Interstitial lung diseases, NSCLC, Systemic scleroderma; as well as potential indication like Colorectal cancer, Malignant-mesothelioma, Ovarian cancer, and Pulmonary fibrosis in the 7MM. A detailed picture of OFEV's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the OFEV for approved and potential indications. The OFEV market report provides insights about OFEV's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OFEV performance, future market assessments inclusive of the OFEV market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OFEV sales forecasts, along with factors driving its market.

OFEV Drug Summary

OFEV is an oral kinase inhibitor developed by Boehringer Ingelheim, FDA-approved since 2014 for idiopathic pulmonary fibrosis (IPF), expanded in 2019 for systemic sclerosis-associated interstitial lung disease (SSc-ILD), and in 2020 for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, as well as in combination with docetaxel for advanced non-small cell lung cancer (NSCLC). As a small-molecule triple angiokinase inhibitor, it potently targets receptors for vascular endothelial growth factor (VEGFR 1-3), fibroblast growth factor (FGFR 1-3), and platelet-derived growth factor (PDGFR a/B), along with FLT3 and CSF1R, thereby inhibiting fibroblast proliferation, myofibroblast transformation, and fibrotic processes while reducing neoangiogenesis and tumor growth in NSCLC. Available as 100 mg and 150 mg soft capsules dosed at 150 mg twice daily (adjusted for body weight <75 kg or tolerability) with food, it commonly causes gastrointestinal side effects like diarrhea, nausea, and vomiting, requiring management with antidiarrheals, alongside risks of liver enzyme elevations, arterial thromboembolism, and bleeding. The report provides OFEV's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the OFEV Market Report

The report provides insights into:

• A comprehensive product overview including the OFEV MoA, description, dosage and administration, research and development activities in approved indications like Idiopathic pulmonary fibrosis, Interstitial lung diseases, NSCLC, Systemic scleroderma; as well as potential indication like Colorectal cancer, Malignant-mesothelioma, Ovarian cancer, and Pulmonary fibrosis.
• Elaborated details on OFEV regulatory milestones and other development activities have been provided in OFEV market report.
• The report also highlights OFEV's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The OFEV market report also covers the patents information, generic entry and impact on cost cut.
• The OFEV market report contains current and forecasted OFEV sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The OFEV market report also features the SWOT analysis with analyst views for OFEV in approved and potential indications.

Methodology:

The OFEV market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OFEV Analytical Perspective by DelveInsight

• In-depth OFEV Market Assessment

This OFEV sales market forecast report provides a detailed market assessment of OFEV for approved indication like Idiopathic pulmonary fibrosis, Interstitial lung diseases, NSCLC, Systemic scleroderma; as well as potential indication like Colorectal cancer, Malignant-mesothelioma, Ovarian cancer, and Pulmonary fibrosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OFEV sales data uptil 2034.

• OFEV Clinical Assessment

The OFEV market report provides the clinical trials information of OFEV for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

OFEV Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

OFEV Market Potential & Revenue Forecast

• Projected market size for the OFEV and its key indications
• Estimated OFEV sales potential (OFEV peak sales forecasts)
• OFEV Pricing strategies and reimbursement landscape

OFEV Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• OFEV Market positioning compared to existing treatments
• OFEV Strengths & weaknesses relative to competitors

OFEV Regulatory & Commercial Milestones

• OFEV Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

OFEV Clinical Differentiation

• OFEV Efficacy & safety advantages over existing drugs
• OFEV Unique selling points

OFEV Market Report Highlights

• In the coming years, the OFEV market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The OFEV companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OFEV's dominance.
• Other emerging products for Idiopathic pulmonary fibrosis, Interstitial lung diseases, NSCLC, Systemic scleroderma; as well as potential indication like Colorectal cancer, Malignant-mesothelioma, Ovarian cancer, and Pulmonary fibrosis are expected to give tough market competition to OFEV and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OFEV in approved and potential indications.
• Analyse OFEV cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted OFEV sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OFEV in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of OFEV? How strong is OFEV's clinical and commercial performance?
• What is OFEV's clinical trial status in each individual indications such as Idiopathic pulmonary fibrosis, Interstitial lung diseases, NSCLC, Systemic scleroderma; as well as potential indication like Colorectal cancer, Malignant-mesothelioma, Ovarian cancer, and Pulmonary fibrosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OFEV Manufacturers?
• What are the key designations that have been granted to OFEV for approved and potential indications? How are they going to impact OFEV's penetration in various geographies?
• What is the current and forecasted OFEV market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of OFEV in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to OFEV for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is OFEV? What is the duration of therapy and what are the geographical variations in cost per patient?